Eupraxia Pharmaceuticals Appoints Dr. Tambiah as CMO to Advance EP-104GI EoE Trial
Eupraxia Pharmaceuticals named board-certified cardiothoracic surgeon Dr. Jeymi Tambiah as Chief Medical Officer, replacing Dr. Mark Kowalski who retires and will serve as a senior consultant. Tambiah’s 18 years in clinical development and regulatory strategy will drive late-stage EP-104GI progress in eosinophilic esophagitis and Gastroenterology pipeline expansion.
1. Leadership Transition
On May 1, Eupraxia Pharmaceuticals appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding Dr. Mark Kowalski, who retires and will continue supporting the company as a senior consultant. This leadership change comes as Eupraxia moves into late-stage trials and broader Gastroenterology development.
2. Professional Background
Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization. She is a board-certified cardiothoracic surgeon with MBChB and MS degrees from the University of Manchester and Imperial College London, and has led immunology programs across pharmaceutical and biotech organizations.
3. Strategic Implications
As CMO, Tambiah will oversee the Phase 1b/2 RESOLVE trial for EP-104GI in eosinophilic esophagitis and guide expansion of the company’s Gastroenterology pipeline using the proprietary Diffusphere™ technology. Her leadership is expected to accelerate upcoming data readouts and regulatory milestones for late-stage assets.